Concepts (238)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Epilepsy | 13 | 2024 | 843 | 2.230 |
Why?
|
| Status Epilepticus | 8 | 2023 | 151 | 2.040 |
Why?
|
| Angelman Syndrome | 3 | 2021 | 65 | 1.840 |
Why?
|
| Seizures | 13 | 2025 | 850 | 1.800 |
Why?
|
| TOR Serine-Threonine Kinases | 6 | 2018 | 415 | 1.650 |
Why?
|
| Electroencephalography | 14 | 2025 | 843 | 1.500 |
Why?
|
| Memory Disorders | 4 | 2017 | 207 | 1.260 |
Why?
|
| PTEN Phosphohydrolase | 3 | 2018 | 252 | 1.220 |
Why?
|
| Hippocampus | 9 | 2018 | 772 | 1.150 |
Why?
|
| Malformations of Cortical Development | 3 | 2018 | 54 | 1.060 |
Why?
|
| Drug Resistant Epilepsy | 7 | 2025 | 226 | 0.950 |
Why?
|
| Disease Models, Animal | 11 | 2024 | 4428 | 0.860 |
Why?
|
| Shal Potassium Channels | 8 | 2012 | 46 | 0.780 |
Why?
|
| Kainic Acid | 3 | 2020 | 21 | 0.730 |
Why?
|
| Sirolimus | 5 | 2018 | 224 | 0.720 |
Why?
|
| Convulsants | 3 | 2017 | 19 | 0.720 |
Why?
|
| Maze Learning | 3 | 2017 | 101 | 0.640 |
Why?
|
| Dendritic Spines | 2 | 2017 | 57 | 0.620 |
Why?
|
| Ubiquitin-Protein Ligases | 2 | 2021 | 353 | 0.590 |
Why?
|
| Arrhythmias, Cardiac | 3 | 2024 | 474 | 0.560 |
Why?
|
| Kv1.1 Potassium Channel | 1 | 2018 | 35 | 0.560 |
Why?
|
| Circadian Rhythm | 1 | 2020 | 305 | 0.540 |
Why?
|
| Poly (ADP-Ribose) Polymerase-1 | 1 | 2017 | 24 | 0.530 |
Why?
|
| Androstadienes | 1 | 2017 | 49 | 0.530 |
Why?
|
| Rats | 11 | 2024 | 3388 | 0.510 |
Why?
|
| Spasms, Infantile | 3 | 2024 | 164 | 0.500 |
Why?
|
| Dendrites | 5 | 2013 | 174 | 0.500 |
Why?
|
| Malformations of Cortical Development, Group I | 1 | 2015 | 3 | 0.480 |
Why?
|
| Extracellular Signal-Regulated MAP Kinases | 1 | 2015 | 135 | 0.450 |
Why?
|
| Animals | 25 | 2024 | 33185 | 0.420 |
Why?
|
| Electrocardiography | 3 | 2024 | 917 | 0.420 |
Why?
|
| Memory | 2 | 2017 | 347 | 0.400 |
Why?
|
| Neurons | 5 | 2017 | 1908 | 0.390 |
Why?
|
| Protein Kinase Inhibitors | 1 | 2017 | 572 | 0.390 |
Why?
|
| Social Behavior | 1 | 2014 | 220 | 0.370 |
Why?
|
| Neocortex | 2 | 2024 | 67 | 0.370 |
Why?
|
| Mitochondria | 1 | 2017 | 722 | 0.370 |
Why?
|
| Benzodiazepines | 3 | 2023 | 106 | 0.360 |
Why?
|
| Mice, Knockout | 7 | 2024 | 3705 | 0.360 |
Why?
|
| Rats, Sprague-Dawley | 7 | 2024 | 1131 | 0.350 |
Why?
|
| Pyramidal Cells | 5 | 2020 | 137 | 0.340 |
Why?
|
| Fear | 3 | 2017 | 199 | 0.340 |
Why?
|
| Mice | 12 | 2024 | 17590 | 0.330 |
Why?
|
| Laser Therapy | 2 | 2023 | 226 | 0.330 |
Why?
|
| Autistic Disorder | 1 | 2014 | 361 | 0.330 |
Why?
|
| Cognition Disorders | 1 | 2014 | 542 | 0.320 |
Why?
|
| Signal Transduction | 3 | 2018 | 4462 | 0.320 |
Why?
|
| Anticonvulsants | 3 | 2023 | 375 | 0.310 |
Why?
|
| Phenotype | 5 | 2021 | 4305 | 0.290 |
Why?
|
| Learning | 1 | 2012 | 355 | 0.290 |
Why?
|
| Time-to-Treatment | 2 | 2020 | 195 | 0.290 |
Why?
|
| Cyclic AMP-Dependent Protein Kinases | 2 | 2006 | 157 | 0.280 |
Why?
|
| Blotting, Western | 4 | 2017 | 1019 | 0.270 |
Why?
|
| Phosphorylation | 8 | 2015 | 1540 | 0.260 |
Why?
|
| Potassium Channels | 6 | 2004 | 150 | 0.250 |
Why?
|
| Male | 21 | 2025 | 62094 | 0.250 |
Why?
|
| Potassium Channels, Voltage-Gated | 5 | 2004 | 59 | 0.250 |
Why?
|
| Small-Conductance Calcium-Activated Potassium Channels | 1 | 2006 | 12 | 0.250 |
Why?
|
| Insulin-Like Growth Factor I | 2 | 2024 | 314 | 0.240 |
Why?
|
| NF-kappa B | 1 | 2007 | 438 | 0.230 |
Why?
|
| Practice Guidelines as Topic | 2 | 2020 | 1224 | 0.210 |
Why?
|
| Cell Membrane | 1 | 2006 | 447 | 0.210 |
Why?
|
| Artifacts | 1 | 2024 | 105 | 0.210 |
Why?
|
| Cochlear Implants | 1 | 2024 | 56 | 0.200 |
Why?
|
| Interneurons | 1 | 2024 | 137 | 0.200 |
Why?
|
| Hemispherectomy | 1 | 2023 | 26 | 0.200 |
Why?
|
| Child | 13 | 2025 | 25070 | 0.200 |
Why?
|
| Hearing Loss, Sensorineural | 1 | 2024 | 154 | 0.190 |
Why?
|
| Transcription, Genetic | 1 | 2007 | 1381 | 0.190 |
Why?
|
| Motor Activity | 2 | 2017 | 504 | 0.180 |
Why?
|
| Child, Preschool | 10 | 2025 | 14350 | 0.180 |
Why?
|
| Tuberous Sclerosis | 1 | 2022 | 121 | 0.180 |
Why?
|
| Female | 16 | 2025 | 67908 | 0.180 |
Why?
|
| Calcineurin | 1 | 2021 | 59 | 0.170 |
Why?
|
| Retrospective Studies | 10 | 2025 | 16782 | 0.170 |
Why?
|
| Minocycline | 1 | 2020 | 42 | 0.170 |
Why?
|
| Professional Practice Gaps | 1 | 2020 | 12 | 0.170 |
Why?
|
| Infant | 9 | 2024 | 12782 | 0.160 |
Why?
|
| Thalamus | 1 | 2020 | 77 | 0.160 |
Why?
|
| Brain Waves | 1 | 2020 | 47 | 0.160 |
Why?
|
| Humans | 22 | 2025 | 125950 | 0.150 |
Why?
|
| Gene Deletion | 2 | 2021 | 768 | 0.150 |
Why?
|
| GABA Modulators | 1 | 2018 | 11 | 0.150 |
Why?
|
| Pentobarbital | 1 | 2018 | 20 | 0.150 |
Why?
|
| Animals, Newborn | 2 | 2024 | 1014 | 0.150 |
Why?
|
| Kv1.4 Potassium Channel | 1 | 2018 | 3 | 0.140 |
Why?
|
| Kv1.2 Potassium Channel | 1 | 2018 | 14 | 0.140 |
Why?
|
| Ion Channels | 2 | 2013 | 200 | 0.140 |
Why?
|
| Guideline Adherence | 1 | 2020 | 365 | 0.140 |
Why?
|
| Pentylenetetrazole | 1 | 2017 | 21 | 0.140 |
Why?
|
| Mice, 129 Strain | 1 | 2017 | 96 | 0.130 |
Why?
|
| Phosphatidylinositol 3-Kinases | 2 | 2017 | 328 | 0.130 |
Why?
|
| Enzyme Inhibitors | 3 | 2017 | 565 | 0.130 |
Why?
|
| Species Specificity | 1 | 2017 | 519 | 0.130 |
Why?
|
| Mice, Inbred C57BL | 2 | 2017 | 4505 | 0.130 |
Why?
|
| Adolescent | 8 | 2025 | 19942 | 0.120 |
Why?
|
| Emergency Medical Services | 1 | 2020 | 399 | 0.120 |
Why?
|
| Ribosomal Protein S6 | 1 | 2015 | 13 | 0.120 |
Why?
|
| Enzyme Activation | 2 | 2015 | 582 | 0.120 |
Why?
|
| MAP Kinase Signaling System | 2 | 2015 | 299 | 0.120 |
Why?
|
| Pilocarpine | 2 | 2013 | 11 | 0.110 |
Why?
|
| Colforsin | 2 | 2006 | 45 | 0.110 |
Why?
|
| Proto-Oncogene Proteins c-akt | 1 | 2017 | 473 | 0.110 |
Why?
|
| Gene Expression Regulation | 2 | 2018 | 2330 | 0.110 |
Why?
|
| Exploratory Behavior | 1 | 2014 | 55 | 0.110 |
Why?
|
| Mutation | 4 | 2021 | 5924 | 0.100 |
Why?
|
| Immunohistochemistry | 2 | 2015 | 1603 | 0.100 |
Why?
|
| Ribosomal Protein S6 Kinases | 1 | 2013 | 48 | 0.100 |
Why?
|
| Gliosis | 1 | 2013 | 35 | 0.100 |
Why?
|
| Tumor Suppressor Proteins | 1 | 2015 | 473 | 0.100 |
Why?
|
| Mechanistic Target of Rapamycin Complex 1 | 1 | 2013 | 167 | 0.090 |
Why?
|
| Potassium | 2 | 2004 | 259 | 0.090 |
Why?
|
| Conditioning, Classical | 1 | 2012 | 53 | 0.090 |
Why?
|
| Multiprotein Complexes | 1 | 2013 | 193 | 0.090 |
Why?
|
| Microglia | 1 | 2013 | 129 | 0.090 |
Why?
|
| Treatment Outcome | 3 | 2023 | 12352 | 0.090 |
Why?
|
| Tetrodotoxin | 2 | 2022 | 44 | 0.090 |
Why?
|
| Dentate Gyrus | 1 | 2011 | 36 | 0.090 |
Why?
|
| Spasm | 2 | 2022 | 44 | 0.090 |
Why?
|
| Nerve Fibers | 1 | 2011 | 66 | 0.090 |
Why?
|
| Behavior, Animal | 1 | 2014 | 493 | 0.090 |
Why?
|
| COS Cells | 3 | 2006 | 249 | 0.090 |
Why?
|
| Neuronal Plasticity | 2 | 2004 | 281 | 0.080 |
Why?
|
| Action Potentials | 3 | 2009 | 459 | 0.080 |
Why?
|
| Channelopathies | 1 | 2009 | 12 | 0.080 |
Why?
|
| Magnetic Resonance Imaging | 2 | 2023 | 3573 | 0.080 |
Why?
|
| Electric Stimulation | 1 | 2009 | 238 | 0.070 |
Why?
|
| Recombinant Fusion Proteins | 2 | 2006 | 724 | 0.060 |
Why?
|
| Intensive Care Units, Pediatric | 2 | 2020 | 471 | 0.060 |
Why?
|
| Magnetoencephalography | 1 | 2025 | 46 | 0.060 |
Why?
|
| Mitogen-Activated Protein Kinase Kinases | 1 | 2005 | 87 | 0.060 |
Why?
|
| Cyclic AMP | 1 | 2006 | 223 | 0.060 |
Why?
|
| Glutathione Transferase | 1 | 2006 | 143 | 0.060 |
Why?
|
| Disease Progression | 1 | 2011 | 2102 | 0.060 |
Why?
|
| Stereotaxic Techniques | 1 | 2025 | 75 | 0.060 |
Why?
|
| Sequence Homology, Amino Acid | 1 | 2006 | 622 | 0.060 |
Why?
|
| Mutagenesis | 1 | 2006 | 333 | 0.060 |
Why?
|
| Electrodes, Implanted | 1 | 2025 | 172 | 0.060 |
Why?
|
| Hospital Mortality | 2 | 2020 | 969 | 0.060 |
Why?
|
| Entorhinal Cortex | 1 | 2004 | 27 | 0.060 |
Why?
|
| Respiration Disorders | 1 | 2024 | 31 | 0.050 |
Why?
|
| Mass Spectrometry | 1 | 2006 | 351 | 0.050 |
Why?
|
| Receptor, IGF Type 1 | 1 | 2024 | 92 | 0.050 |
Why?
|
| Valine | 1 | 2004 | 105 | 0.050 |
Why?
|
| Calcium-Calmodulin-Dependent Protein Kinases | 1 | 2004 | 101 | 0.050 |
Why?
|
| Diazepam | 1 | 2023 | 20 | 0.050 |
Why?
|
| Policy | 1 | 2023 | 34 | 0.050 |
Why?
|
| Epilepsy, Temporal Lobe | 1 | 2004 | 84 | 0.050 |
Why?
|
| Magnetic Resonance Spectroscopy | 1 | 2023 | 277 | 0.050 |
Why?
|
| Amino Acid Sequence | 1 | 2006 | 2550 | 0.050 |
Why?
|
| Repressor Proteins | 2 | 2004 | 765 | 0.040 |
Why?
|
| Schools | 1 | 2023 | 232 | 0.040 |
Why?
|
| Students | 1 | 2023 | 247 | 0.040 |
Why?
|
| Molecular Sequence Data | 1 | 2006 | 3600 | 0.040 |
Why?
|
| Sodium Channel Blockers | 1 | 2020 | 22 | 0.040 |
Why?
|
| Phenobarbital | 1 | 2020 | 30 | 0.040 |
Why?
|
| Phenytoin | 1 | 2020 | 57 | 0.040 |
Why?
|
| Electrocorticography | 1 | 2020 | 63 | 0.040 |
Why?
|
| Rats, Wistar | 1 | 2020 | 306 | 0.040 |
Why?
|
| Predictive Value of Tests | 1 | 2025 | 2173 | 0.040 |
Why?
|
| Mutagenesis, Site-Directed | 3 | 2005 | 299 | 0.040 |
Why?
|
| Patch-Clamp Techniques | 3 | 2004 | 270 | 0.040 |
Why?
|
| Cerebral Palsy | 1 | 2020 | 80 | 0.040 |
Why?
|
| Infusions, Intravenous | 1 | 2020 | 523 | 0.040 |
Why?
|
| Protein Subunits | 3 | 2005 | 162 | 0.040 |
Why?
|
| Sequence Analysis, RNA | 1 | 2021 | 416 | 0.040 |
Why?
|
| Oocytes | 3 | 2005 | 278 | 0.040 |
Why?
|
| Multivariate Analysis | 1 | 2020 | 1349 | 0.030 |
Why?
|
| Dose-Response Relationship, Drug | 1 | 2020 | 1597 | 0.030 |
Why?
|
| Proportional Hazards Models | 1 | 2020 | 1343 | 0.030 |
Why?
|
| Heart | 1 | 2021 | 645 | 0.030 |
Why?
|
| Gene Expression | 1 | 2021 | 1489 | 0.030 |
Why?
|
| Sex Factors | 1 | 2020 | 1292 | 0.030 |
Why?
|
| Evidence-Based Medicine | 1 | 2020 | 604 | 0.030 |
Why?
|
| Cohort Studies | 1 | 2025 | 4892 | 0.030 |
Why?
|
| Case-Control Studies | 1 | 2023 | 3297 | 0.030 |
Why?
|
| Nerve Tissue Proteins | 1 | 2002 | 1075 | 0.030 |
Why?
|
| Pandemics | 1 | 2023 | 1125 | 0.030 |
Why?
|
| Hospitals, Pediatric | 1 | 2020 | 775 | 0.030 |
Why?
|
| Developmental Disabilities | 1 | 2020 | 714 | 0.030 |
Why?
|
| Length of Stay | 1 | 2020 | 1314 | 0.030 |
Why?
|
| Protein Kinases | 2 | 2009 | 321 | 0.030 |
Why?
|
| Xenopus laevis | 2 | 2005 | 118 | 0.030 |
Why?
|
| Age Factors | 1 | 2020 | 2762 | 0.030 |
Why?
|
| Membrane Potentials | 2 | 2004 | 294 | 0.030 |
Why?
|
| Kv Channel-Interacting Proteins | 2 | 2004 | 33 | 0.030 |
Why?
|
| Prospective Studies | 1 | 2024 | 6167 | 0.030 |
Why?
|
| Intellectual Disability | 1 | 2020 | 1046 | 0.020 |
Why?
|
| Amino Acid Substitution | 2 | 2005 | 397 | 0.020 |
Why?
|
| Structure-Activity Relationship | 2 | 2004 | 567 | 0.020 |
Why?
|
| Calcium-Binding Proteins | 2 | 2004 | 324 | 0.020 |
Why?
|
| Protein Processing, Post-Translational | 2 | 2004 | 348 | 0.020 |
Why?
|
| Follow-Up Studies | 1 | 2018 | 5089 | 0.020 |
Why?
|
| Hypertrophy | 1 | 2009 | 101 | 0.020 |
Why?
|
| United States | 1 | 2023 | 11159 | 0.020 |
Why?
|
| Young Adult | 1 | 2020 | 9596 | 0.020 |
Why?
|
| Immunosuppressive Agents | 1 | 2009 | 641 | 0.010 |
Why?
|
| GABA Antagonists | 1 | 2004 | 16 | 0.010 |
Why?
|
| Bicuculline | 1 | 2004 | 16 | 0.010 |
Why?
|
| Cyclic Nucleotide-Gated Cation Channels | 1 | 2004 | 16 | 0.010 |
Why?
|
| Excitatory Amino Acid Agonists | 1 | 2004 | 17 | 0.010 |
Why?
|
| Hyperpolarization-Activated Cyclic Nucleotide-Gated Channels | 1 | 2004 | 13 | 0.010 |
Why?
|
| 1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine | 1 | 2004 | 4 | 0.010 |
Why?
|
| 4-Aminopyridine | 1 | 2004 | 27 | 0.010 |
Why?
|
| Butadienes | 1 | 2004 | 22 | 0.010 |
Why?
|
| Cell Physiological Phenomena | 1 | 2004 | 16 | 0.010 |
Why?
|
| Subcellular Fractions | 1 | 2004 | 87 | 0.010 |
Why?
|
| Excitatory Postsynaptic Potentials | 1 | 2004 | 102 | 0.010 |
Why?
|
| Potassium Channel Blockers | 1 | 2004 | 84 | 0.010 |
Why?
|
| Xenopus | 1 | 2004 | 103 | 0.010 |
Why?
|
| Protein Kinase C | 1 | 2004 | 111 | 0.010 |
Why?
|
| Nitriles | 1 | 2004 | 141 | 0.010 |
Why?
|
| Cricetinae | 1 | 2004 | 364 | 0.010 |
Why?
|
| Mitogen-Activated Protein Kinases | 1 | 2004 | 186 | 0.010 |
Why?
|
| Molecular Structure | 1 | 2004 | 305 | 0.010 |
Why?
|
| In Vitro Techniques | 1 | 2004 | 821 | 0.010 |
Why?
|
| Calcium-Calmodulin-Dependent Protein Kinase Type 2 | 1 | 2004 | 139 | 0.010 |
Why?
|
| Protein Isoforms | 1 | 2004 | 403 | 0.010 |
Why?
|
| 8-Bromo Cyclic Adenosine Monophosphate | 1 | 2002 | 20 | 0.010 |
Why?
|
| Phosphopeptides | 1 | 2002 | 25 | 0.010 |
Why?
|
| Analysis of Variance | 1 | 2004 | 950 | 0.010 |
Why?
|
| Macromolecular Substances | 1 | 2002 | 141 | 0.010 |
Why?
|
| Gene Transfer Techniques | 1 | 2004 | 334 | 0.010 |
Why?
|
| Ion Transport | 1 | 2002 | 48 | 0.010 |
Why?
|
| Muscle Proteins | 1 | 2004 | 389 | 0.010 |
Why?
|
| Pyrimidines | 1 | 2004 | 393 | 0.010 |
Why?
|
| Up-Regulation | 1 | 2004 | 828 | 0.010 |
Why?
|
| Transfection | 1 | 2002 | 949 | 0.010 |
Why?
|
| Models, Neurological | 1 | 2002 | 185 | 0.010 |
Why?
|
| Cytoskeletal Proteins | 1 | 2002 | 274 | 0.010 |
Why?
|
| Binding Sites | 1 | 2002 | 1193 | 0.010 |
Why?
|
| Heart Diseases | 1 | 2004 | 484 | 0.010 |
Why?
|
| Myocardium | 1 | 2004 | 835 | 0.010 |
Why?
|
| Models, Molecular | 1 | 2002 | 1065 | 0.010 |
Why?
|
| Cells, Cultured | 1 | 2004 | 2901 | 0.010 |
Why?
|
| Synapses | 1 | 2002 | 430 | 0.010 |
Why?
|
| Alzheimer Disease | 1 | 2004 | 835 | 0.010 |
Why?
|
| Brain | 1 | 2004 | 3021 | 0.010 |
Why?
|